Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for advanced prostate cancer, at the European Society for Medical Oncology ...

Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific ...

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU’s total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

Celcuity reported past Phase 3 and Phase 1b/2 data at ESMO 2026 showing that gedatolisib regimens improved progression-free ...

Exact Imaging is looking to broaden uptake of its high-resolution micro-ultrasound system for prostate cancer screening and is boosting its commercial team to help. The company markets ExactVu, a ...

ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and surgical nerve repair. ... Read More The post ASX healthcare stocks advance ...

Some of the biggest NFL stars are coming together to share an important message about men’s health. During the 2026 Super Bowl on Sunday (February 8), Novartis AG, a multinational pharmaceutical ...

The potential new indication could significantly expand Nubeqa's market, with the target population accounting for an estimated 15% of new prostate cancer diagnoses. (iStock/Getty Images Plus) Bayer’s ...

The FDA today expanded the approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) to men with metastatic prostate cancer that has not been treated with androgen pathway dru ...